![]() |
|
|||
|
By Michelle Knight knight@theacorn.com An Amgen-created drug received the green light last month for use by cancer patients to reduce the risk of bone complications. Denosumab, brand name XGEVA, was approved by the U.S. Food and Drug Administration on Nov. 18. read more
|
| Thread Tools | |
| Display Modes | |
|
|